Xilio Therapeutics (XLO)
Xilio Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
400K
Short interest
settlement 2026-10-15
41.2
Days to cover
-3.4 days vs prior
52.4%
Short share of volume
2026-11-02
46
Fails to deliver
settlement 2026-10-13
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in XLO is 400,316 shares, down 12,647 shares over the last month. Over the last 48 readings it ranged from 41,958 shares (15 November 2024) to 6,913,181 shares (14 November 2025). The latest reading sits at the bottom of that range. At the reported average volume of 10K shares a day that is 41.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/xlo" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 400,316 | -2.4% | 9,727 | 41.16 |
| 2026-09-30 | 410,050 | -0.7% | 9,210 | 44.52 |
| 2026-09-15 | 412,963 | -1.3% | 11,055 | 37.36 |
| 2026-08-31 | 418,277 | -0.9% | 10,705 | 39.07 |
| 2026-08-14 | 421,921 | -0.9% | 13,340 | 31.63 |
| 2026-07-31 | 425,882 | +58.8% | 34,680 | 12.28 |
| 2026-07-15 | 268,180 | +53.6% | 59,349 | 4.52 |
| 2026-06-30 | 174,619 | +0.7% | 47,868 | 3.65 |
| 2026-06-15 | 173,470 | +5.0% | 24,458 | 7.09 |
| 2026-05-29 | 165,274 | -3.6% | 30,465 | 5.43 |
| 2026-05-15 | 171,370 | +5.2% | 95,033 | 1.80 |
| 2026-04-30 | 162,958 | -6.5% | 32,972 | 4.94 |
| 2026-04-15 | 174,319 | -4.5% | 29,431 | 5.92 |
| 2026-03-31 | 182,492 | -91.8% | 58,298 | 3.13 |
| 2026-03-13 | 2,231,716 | +5.6% | 480,808 | 4.64 |
| 2026-02-27 | 2,113,748 | -1.9% | 312,226 | 6.77 |
| 2026-02-13 | 2,155,562 | +0.8% | 602,303 | 3.58 |
| 2026-01-30 | 2,139,403 | +2.4% | 516,334 | 4.14 |
| 2026-01-15 | 2,088,847 | -3.7% | 358,062 | 5.83 |
| 2025-12-31 | 2,168,608 | -29.8% | 269,707 | 8.04 |
| 2025-12-15 | 3,088,368 | -53.7% | 737,184 | 4.19 |
| 2025-11-28 | 6,675,820 | -3.4% | 372,254 | 17.93 |
| 2025-11-14 | 6,913,181 | +12.3% | 1,166,847 | 5.92 |
| 2025-10-31 | 6,156,308 | +17.2% | 717,816 | 8.58 |
| 2025-10-15 | 5,251,586 | +1.7% | 422,788 | 12.42 |
| 2025-09-30 | 5,162,356 | +4.8% | 386,950 | 13.34 |
| 2025-09-15 | 4,923,762 | +14.5% | 1,458,919 | 3.37 |
| 2025-08-29 | 4,300,761 | -0.2% | 396,203 | 10.85 |
| 2025-08-15 | 4,308,767 | +12.7% | 452,484 | 9.52 |
| 2025-07-31 | 3,821,839 | +14.5% | 369,460 | 10.34 |
| 2025-07-15 | 3,338,281 | +0.6% | 312,275 | 10.69 |
| 2025-06-30 | 3,317,060 | +26.4% | 468,345 | 7.08 |
| 2025-06-13 | 2,624,728 | +231.6% | 1,283,725 | 2.04 |
| 2025-05-30 | 791,482 | -35.1% | 608,421 | 1.30 |
| 2025-05-15 | 1,219,174 | +247.2% | 4,687,108 | 1.00 |
| 2025-04-30 | 351,157 | -37.5% | 201,665 | 1.74 |
| 2025-04-15 | 562,279 | -12.8% | 205,501 | 2.74 |
| 2025-03-31 | 644,535 | +12.0% | 257,705 | 2.50 |
| 2025-03-14 | 575,448 | -17.2% | 664,576 | 1.00 |
| 2025-02-28 | 694,611 | -61.6% | 2,467,829 | 1.00 |
| 2025-02-14 | 1,810,353 | +809.5% | 19,533,955 | 1.00 |
| 2025-01-31 | 199,049 | -6.6% | 488,146 | 1.00 |
| 2025-01-15 | 213,071 | -44.5% | 362,702 | 1.00 |
| 2024-12-31 | 384,094 | +221.6% | 1,523,795 | 1.00 |
| 2024-12-13 | 119,440 | -31.9% | 81,906 | 1.46 |
| 2024-11-29 | 175,269 | +317.7% | 154,586 | 1.13 |
| 2024-11-15 | 41,958 | -89.4% | 362,661 | 1.00 |
| 2024-10-31 | 396,085 | +278.1% | 476,772 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of XLO volume is 52.4%, up 16.0 points over the last five sessions. Over the last 30 readings it ranged from 4.6% (6 October 2026) to 78.0% (23 September 2026). The latest reading is 14.9 points above the 30-session average of 37.5%, on 4K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 2K | 4K | 52.4% | 0 |
| 2026-10-30 | 1K | 4K | 30.8% | 0 |
| 2026-10-29 | 109 | 877 | 12.4% | 0 |
| 2026-10-28 | 4K | 10K | 37.8% | 0 |
| 2026-10-27 | 6K | 12K | 47.5% | 0 |
| 2026-10-26 | 6K | 17K | 36.4% | 0 |
| 2026-10-23 | 3K | 8K | 37.0% | 200 |
| 2026-10-22 | 1K | 3K | 30.9% | 0 |
| 2026-10-21 | 6K | 14K | 46.8% | 0 |
| 2026-10-20 | 2K | 5K | 39.2% | 0 |
| 2026-10-19 | 1K | 5K | 19.8% | 0 |
| 2026-10-16 | 591 | 3K | 16.9% | 0 |
| 2026-10-15 | 2K | 5K | 35.1% | 0 |
| 2026-10-14 | 2K | 3K | 52.9% | 0 |
| 2026-10-13 | 1K | 5K | 28.5% | 0 |
| 2026-10-12 | 943 | 3K | 27.7% | 0 |
| 2026-10-09 | 581 | 3K | 18.4% | 0 |
| 2026-10-08 | 1K | 3K | 32.2% | 0 |
| 2026-10-07 | 24 | 166 | 14.5% | 0 |
| 2026-10-06 | 104 | 2K | 4.6% | 0 |
| 2026-10-05 | 1K | 2K | 67.9% | 0 |
| 2026-10-02 | 1K | 2K | 64.3% | 0 |
| 2026-10-01 | 599 | 2K | 28.5% | 0 |
| 2026-09-30 | 51 | 677 | 7.5% | 0 |
| 2026-09-29 | 589 | 1K | 54.3% | 0 |
| 2026-09-28 | 691 | 2K | 32.7% | 0 |
| 2026-09-25 | 1K | 2K | 75.8% | 0 |
| 2026-09-24 | 3K | 6K | 46.7% | 500 |
| 2026-09-23 | 131 | 168 | 78.0% | 0 |
| 2026-09-22 | 1K | 3K | 46.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in XLO is 46 shares, up 44 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (9 October 2026) to 3,621 shares (1 October 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 46 | $9.15 | $421 |
| 2026-10-09 | 2 | $9.01 | $18 |
| 2026-10-07 | 61 | $8.97 | $547 |
| 2026-10-05 | 961 | $8.96 | $9K |
| 2026-10-01 | 3,621 | $9.05 | $33K |
| 2026-09-30 | 311 | $9.19 | $3K |
| 2026-09-29 | 291 | $9.05 | $3K |
| 2026-09-28 | 269 | $9.04 | $2K |
| 2026-09-25 | 460 | $9.00 | $4K |
| 2026-09-21 | 2,087 | $9.13 | $19K |
| 2026-09-18 | 2,609 | $9.04 | $24K |
| 2026-09-17 | 1,695 | $8.98 | $15K |
| 2026-09-16 | 2,368 | $9.03 | $21K |
| 2026-09-15 | 581 | $8.93 | $5K |
| 2026-09-14 | 115 | $8.93 | $1K |
| 2026-09-11 | 258 | $8.93 | $2K |
| 2026-09-09 | 58 | $8.91 | $517 |
| 2026-09-08 | 161 | $9.00 | $1K |
| 2026-09-01 | 131 | $8.95 | $1K |
| 2026-08-21 | 881 | $9.23 | $8K |
| 2026-08-20 | 742 | $9.41 | $7K |
| 2026-08-19 | 582 | $9.50 | $6K |
| 2026-08-18 | 198 | $9.49 | $2K |
| 2026-08-17 | 2,032 | $9.17 | $19K |
| 2026-08-14 | 501 | $9.01 | $5K |
| 2026-08-13 | 1,588 | $9.05 | $14K |
| 2026-08-10 | 15 | $9.11 | $137 |
| 2026-08-07 | 1,203 | $9.27 | $11K |
| 2026-08-06 | 1,445 | $9.11 | $13K |
| 2026-08-05 | 2,601 | $9.09 | $24K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for XLO in the last 90 days. The most recent filings are listed below. Latest filing: Shannon James Samuel (Director) on 2026-03-26.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Director | Buy | 5K | $8.79 | $44K | 10K |
| 2026-01-02 | Frankenfield Christopher James | Chief Financial Officer | Sell | 7K | $0.64 | $4K | 25K |
| 2026-01-02 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Sell | 2K | $0.64 | $1K | 6K |
| 2026-01-01 | Russo Rene | PRESIDENT AND CEO | Exercise or conversion | 44K | price not stated in the filing | not stated | 325K |
| 2026-01-01 | Frankenfield Christopher James | Chief Financial Officer | Exercise or conversion | 19K | price not stated in the filing | not stated | 32K |
| 2026-01-01 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Exercise or conversion | 5K | price not stated in the filing | not stated | 8K |
| 2026-01-01 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Exercise or conversion | 17K | price not stated in the filing | not stated | 33K |
| 2025-06-17 | Shannon James Samuel | Director | Buy | 25K | $0.69 | $17K | 70K |
| 2025-06-16 | Shannon James Samuel | Director | Buy | 45K | $0.69 | $31K | 45K |
| 2025-06-16 | Russo Rene | PRESIDENT AND CEO | Buy | 36K | $0.68 | $25K | 281K |
| 2025-01-02 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Sell | 2K | $0.98 | $2K | 3K |
| 2025-01-02 | Frankenfield Christopher James | Chief Financial Officer | Sell | 7K | $0.98 | $7K | 12K |
| 2025-01-01 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Exercise or conversion | 5K | price not stated in the filing | not stated | 5K |
| 2025-01-01 | Russo Rene | PRESIDENT AND CEO | Exercise or conversion | 44K | price not stated in the filing | not stated | 245K |
| 2025-01-01 | Luptakova Katarina | CHIEF MEDICAL OFFICER | Exercise or conversion | 17K | price not stated in the filing | not stated | 17K |
| 2025-01-01 | Frankenfield Christopher James | Chief Financial Officer | Exercise or conversion | 19K | price not stated in the filing | not stated | 19K |
| 2024-12-18 | GILEAD SCIENCES, INC. | TenPercentOwner | Buy | 1.8M | $1.04 | $1.8M | 9.1M |
| 2024-04-02 | GILEAD SCIENCES, INC. | TenPercentOwner | Buy | 485K | $0.76 | $369K | 7.3M |
| 2024-02-08 | Atlas Venture Fund XI, L.P. | TenPercentOwner | Sell | 733 | $0.64 | $469 | 2.0M |
| 2024-02-08 | Atlas Venture Fund XI, L.P. | TenPercentOwner | Sell | 267 | $0.64 | $171 | 735K |
| 2024-01-12 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | Sell | 2K | $0.83 | $1K | 2.0M |
| 2024-01-12 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | Sell | 560 | $0.83 | $465 | 735K |
| 2024-01-11 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | Sell | 569 | $0.87 | $495 | 735K |
| 2024-01-11 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | Sell | 2K | $0.87 | $1K | 2.0M |
| 2021-12-10 | BCIP Life Sciences Associates, LP | TenPercentOwner | Buy | 22K | $9.56 | $209K | 2.8M |
| 2021-12-10 | BCIP Life Sciences Associates, LP | TenPercentOwner | Buy | 3K | $10.24 | $33K | 2.8M |
| 2021-12-09 | BCIP Life Sciences Associates, LP | TenPercentOwner | Buy | 4K | $9.84 | $39K | 2.8M |
| 2021-12-08 | BCIP Life Sciences Associates, LP | TenPercentOwner | Buy | 13K | $9.62 | $129K | 2.8M |
| 2021-10-26 | Alexandria Venture Investments, LLC | TenPercentOwner | Conversion | 166K | price not stated in the filing | not stated | 166K |
| 2021-10-26 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | Buy | 188K | $16.00 | $3.0M | 736K |
| 2021-10-26 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | Conversion | 1.4M | price not stated in the filing | not stated | 1.4M |
| 2021-10-26 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | Conversion | 624K | price not stated in the filing | not stated | 2.0M |
| 2021-10-26 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | Conversion | 548K | price not stated in the filing | not stated | 548K |
| 2021-10-26 | BAY CITY CAPITAL LLC | TenPercentOwner | Buy | 313K | $16.00 | $5.0M | 1.1M |
| 2021-10-26 | BAY CITY CAPITAL LLC | TenPercentOwner | Conversion | 666K | price not stated in the filing | not stated | 666K |
| 2021-10-26 | BAY CITY CAPITAL LLC | TenPercentOwner | Conversion | 151K | price not stated in the filing | not stated | 817K |
| 2021-10-26 | Merck KGaA | TenPercentOwner | Conversion | 416K | price not stated in the filing | not stated | 416K |
| 2021-10-26 | Merck KGaA | TenPercentOwner | Conversion | 265K | price not stated in the filing | not stated | 681K |
| 2021-10-26 | Rock Springs Capital Master Fund LP | TenPercentOwner | Conversion | 756K | price not stated in the filing | not stated | 756K |
| 2021-10-26 | Rock Springs Capital Master Fund LP | TenPercentOwner | Conversion | 151K | price not stated in the filing | not stated | 151K |
| 2021-10-26 | Rock Springs Capital Master Fund LP | TenPercentOwner | Buy | 500K | $16.00 | $8.0M | 1.3M |
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | TenPercentOwner | Buy | 250K | $16.00 | $4.0M | 1.4M |
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | TenPercentOwner | Conversion | 832K | price not stated in the filing | not stated | 832K |
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | TenPercentOwner | Conversion | 359K | price not stated in the filing | not stated | 1.2M |
| 2021-10-26 | Takeda Ventures, Inc. | TenPercentOwner | Conversion | 1.5M | price not stated in the filing | not stated | 1.5M |
| 2021-10-26 | SV7 (IMF) GP LLP | TenPercentOwner | Conversion | 303K | price not stated in the filing | not stated | 1.3M |
| 2021-10-26 | SV7 (IMF) GP LLP | TenPercentOwner | Conversion | 999K | price not stated in the filing | not stated | 999K |
| 2021-10-26 | FMR LLC | Other | Conversion | 789K | price not stated in the filing | not stated | 816K |
| 2021-10-26 | FMR LLC | Other | Conversion | 372K | price not stated in the filing | not stated | 372K |
| 2021-10-26 | FMR LLC | Other | Conversion | 29K | price not stated in the filing | not stated | 1.5M |
| 2021-10-26 | FMR LLC | Other | Conversion | 686K | price not stated in the filing | not stated | 1.5M |
| 2021-10-26 | FMR LLC | Other | Conversion | 4K | price not stated in the filing | not stated | 4K |
| 2021-10-26 | FIL Ltd | Other | Conversion | 219K | price not stated in the filing | not stated | 219K |
| 2021-10-26 | Deerfield Mgmt L.P. | TenPercentOwnerOther | Conversion | 756K | price not stated in the filing | not stated | 756K |
| 2021-10-26 | Deerfield Mgmt L.P. | TenPercentOwnerOther | Buy | 388K | $16.00 | $6.2M | 1.1M |
| 2021-10-26 | SV7 Impact Medicine Fund LP | TenPercentOwner | Buy | 313K | $16.00 | $5.0M | 1.6M |
| 2021-10-26 | SV7 Impact Medicine Fund LP | TenPercentOwner | Conversion | 303K | price not stated in the filing | not stated | 1.3M |
| 2021-10-26 | SV7 Impact Medicine Fund LP | TenPercentOwner | Conversion | 999K | price not stated in the filing | not stated | 999K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON17 holders report 5% or more of XLO in their latest filing, all on Schedule 13G (passive). The largest reported stake is GILEAD SCIENCES, INC. at 19.9% of the class (14,517,678 shares), filed 2026-02-12 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 2 | StemPoint Capital Management GP LLCother entity | 629K | 9.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | StemPoint Capital LPinvestment adviser, partnership | 629K | 9.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Michelle Rossparent holding company, individual | 629K | 9.5% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 4 | BCLS II Equity Opportunities, LPpartnership | 664K | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Bain Capital Life Sciences Fund II, L.P.partnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BCIP Life Sciences Associates, LPpartnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G | ORBIMED ADVISORS LLCinvestment adviser | 642K | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G | OrbiMed Capital GP X LLCother entity | 482K | 7.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Point72 Asset Management, L.P.partnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Point72 Capital Advisors, Inc.corporation | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Steven A. Cohenindividual | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G | Sirenia Capital Management LPinvestment adviser, partnership | 1.1M | 9.9% | 2026-03-31 |
| 2026-05-15 | 13G | Alex Silversteinparent holding company, individual | 1.1M | 9.9% | 2026-03-31 |
| 2026-02-17 | 13G/Ano. 3 | BCLS II Investco, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLSP, L.P.partnership | 4.7M | 6.7% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Frazier Life Sciences Public Fund, L.P.partnership | 4.7M | 6.7% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLSP, L.L.C.other entity | 4.7M | 6.7% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS XII, L.L.C.other entity | 693K | 1.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS XII, L.P.partnership | 693K | 1.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Frazier Life Sciences XII, L.P.partnership | 693K | 1.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS XI, L.P.partnership | 397K | 0.6% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Frazier Life Sciences XI, L.P.partnership | 397K | 0.6% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS XI, L.L.C.other entity | 397K | 0.6% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS X, L.L.C.other entity | 149K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS X, L.P.partnership | 149K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Frazier Life Sciences X, L.P.partnership | 149K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Patrick J. Heronindividual | 149K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | James N. Topperindividual | 149K | 0.2% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 3 | GILEAD SCIENCES, INC.corporation | 14.5M | 19.9% | 2025-12-31 |
| 2025-12-11 | 13G | Coastlands Capital LPinvestment adviser, partnership | 5.3M | 10.0% | 2025-12-04 |
| 2025-12-11 | 13G | Coastlands Capital Partners LPpartnership | 5.3M | 10.0% | 2025-12-04 |
| 2025-12-11 | 13G | Coastlands Capital GP LLCother entity | 5.3M | 10.0% | 2025-12-04 |
| 2025-12-11 | 13G | Coastlands Capital LLCparent holding company, other entity | 5.3M | 10.0% | 2025-12-04 |
| 2025-12-11 | 13G | Matthew D. Perryparent holding company, individual | 5.3M | 10.0% | 2025-12-04 |
13F holders
Tracked managers holding XLO at their latest 13F. JSON3 of the 30 tracked managers held XLO at their latest 13F, $1.0M in total at quarter-end prices. Renaissance Technologies is the largest at $615K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 64K | $615K | 0.00% | +15K |
| Citadel Advisors | 2026-06-30 | 26K | $249K | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 15K | $139K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Xilio Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Xilio Therapeutics (XLO), SEC CIK 1840233, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-03-26.JSON and CSV
- Company record
- EDGAR filing index for CIK 1840233Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of XLO is sold short?
400,316 shares were held short at the 2026-10-15 settlement, 41.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is XLO's daily short volume?
On 2026-11-02, 1,833 of the 3,501 XLO shares reported to FINRA were sold short, 52.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does XLO have fails to deliver?
The SEC's latest file shows 46 XLO shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are XLO insiders buying or selling?
No open-market insider trades were reported for XLO in the last 90 days. The most recent filings are listed below. Latest filing: Shannon James Samuel (Director) on 2026-03-26.
Who owns 5% or more of XLO?
17 holders report 5% or more of XLO in their latest filing, all on Schedule 13G (passive). The largest reported stake is GILEAD SCIENCES, INC. at 19.9% of the class (14,517,678 shares), filed 2026-02-12 for an event on 2025-12-31.
Which tracked 13F managers own XLO?
3 of the 30 tracked 13F managers held XLO shares at their latest filing, $1.0M in all. The largest: Renaissance Technologies (64K shares, $615K), Ken Griffin's Citadel Advisors (26K shares, $249K), Two Sigma Investments (15K shares, $139K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.